ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

axatilimab

Also written as “Axatilimab”, “INCA034176” and “SNDX-6352”.

Its studies are mostly in Bronchiolitis Obliterans Syndrome · Idiopathic Pulmonary Fibrosis · Neoplasm Metastasis · Coronavirus Infections, led by 2 companies.

Drug pageAxatilimab: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 9, 202412 company-led studies, 7 open or runningNext primary completion: Jan 6, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyteits history only76 open or runningphase 3since Feb 9, 2024Feb 9, 2024Jan 6, 2027phase 2 · NCT06843408
Syndax Pharmaceuticals51 open or runningphase 2since Jul 10, 2018Jun 30, 2017none ahead

Also a collaborator on its studies: DevPro Biopharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Syndax Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 30, 2017First study: phase 1 study in Neoplasm MetastasisFirst studyNCT03238027 · 45 enrolled · United States
  2. Jul 10, 2018Phase 2 study in Bronchiolitis Obliterans SyndromeNCT03604692 · 41 enrolled · United States
  3. Jun 9, 2019Named axatilimabINNProposed as its International Nonproprietary Name in WHO's List 121 · before, INCA034176, SNDX-6352
  4. May 29, 2020Phase 2 study in Coronavirus InfectionsNCT04415073 · 1 enrolled · United States
  5. Jan 5, 2021Phase 2 study in Bronchiolitis Obliterans SyndromeNCT04710576 · 296 planned · United States, Australia, Belgium and more
  6. Nov 9, 2023Phase 2 study in Idiopathic Pulmonary FibrosisNCT06132256 · 145 enrolled · Australia, Belgium, Canada and more

TargetBeta

CSF1R →read by rule
“A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against colony-stimulating factor 1 receptor (CSF-1R; CSF1R; macrophage-CSFR; M-CSFR; CD115; c-fms), ”NCIt, by rule
“Macrophage colony stimulating factor receptor inhibitor”ChEMBL 37, by rule

Other programs on CSF1R

ProgramCompanyFurthest phaseStudies
quizartinibruleDaiichi Sankyophase 322
pimicotinibruleAbbisko Caymanphase 314
vimseltinibruleOno Pharmaceuticalphase 38
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38
adrixetinibrulequrient-co-ltdphase 23

Studies

All 5 Syndax Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06132256Idiopathic Pulmonary Fibrosis · Australia, Belgium, Canada and more2CompletedAug 27, 2026145
NCT04710576Bronchiolitis Obliterans Syndrome · United States, Australia, Belgium and more2RecruitingApr 7, 2023296
NCT04415073Coronavirus Infections · United States2TerminatedJul 13, 20201
NCT03604692Bronchiolitis Obliterans Syndrome · United States2CompletedAug 12, 202241
NCT03238027Neoplasm Metastasis · United States1CompletedNov 20, 202045

How it is read

Names in the registry

  • “Axatilimab”, 5 entries
  • “INCA034176”, 5 entries
  • “axatilimab”, 1 entry
  • “SNDX-6352”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.